Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Epidemiology Study of Keloid

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Tirgan, Michael H., M.D.
Information provided by (Responsible Party):
Tirgan, Michael H., M.D. Identifier:
First received: August 23, 2011
Last updated: October 17, 2016
Last verified: October 2016
Although keloid is a very common condition; there are no statistics as to its true incidence and prevalence, neither in United States, nor elsewhere in the world. This trial intends to capture epidemiological data about this disease in a large population sample.


Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Epidemiology Study of Keloid

Further study details as provided by Tirgan, Michael H., M.D.:

Primary Outcome Measures:
  • Prevalence of various clinical findings will be determined at the end of Survey. [ Time Frame: Two Years ] [ Designated as safety issue: No ]
    This will be a prospective online and paper based survey with an estimated 100,000 responders participating in two years. Statistics will be descriptive. The prevalence of various clinical findings will be determined at the end of Survey. Findings will be correlated with the source of the data, online, or paper questionnaire, as well as the locations where the paper questionnaires surveys were placed.

Estimated Enrollment: 100000
Study Start Date: September 2011
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
Random Populations
The aim of this study is to determine the prevalence and incidence of keloid in large populations.

Detailed Description:
The purpose of current trial is to establish a robust database of incidence and prevalence of keloid, as well as prevalence of familial keloid, in various ethnic groups. Study sample size is 100,000 random individuals who will fill out either a web survery or a paper questionnaire.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
General population will be sampled randomly

Inclusion Criteria:

  1. Informed consent
  2. Age above 18 to answer the survey questions
  3. Parents shall respond on behalf of their minor children

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01423383

Contact: Michael H. Tirgan, MD (212) 874 4200

United States, New York
Michael H. Tirgan, MD Recruiting
New York, New York, United States, 10023
Contact: Michael H. Tirgan, MD    212-874-4200   
Principal Investigator: Michael H. Tirgan, MD         
Sponsors and Collaborators
Tirgan, Michael H., M.D.
Study Chair: Michael H. Tirgan, MD St. Luke's-Roosevelt Hospital Center
  More Information

Additional Information:
Responsible Party: Tirgan, Michael H., M.D. Identifier: NCT01423383     History of Changes
Other Study ID Numbers: Tirgan 11-04 
Study First Received: August 23, 2011
Last Updated: October 17, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Tirgan, Michael H., M.D.:

Additional relevant MeSH terms:
Collagen Diseases
Connective Tissue Diseases
Pathologic Processes processed this record on October 27, 2016